Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amgen
Denosumab Achieved Superior Bone Mineral Density Gains in Head-to-Head Trial versus Weekly Alendronate FOSAMAX
June 12th, 2008
Amgen (NASDAQ: AMGN) announced complete results from a head-to-head, double-blind study comparing the effects of twice-yearly subcutaneous injections of denosumab versus weekly oral doses of alendronate (FOSAMAX(R)) on bone mineral density (BMD) in postmenopausal women with low BMD. The results were presented during a late breaking session at this year's 35th Annual European Symposium on Calcified Tissues (ECTS) meeting. Top-line results of this study were previously reported in January 2008. In the non-pivotal Phase 3 study, administration of denosumab resulted in significantly greater BMD gains at all sites measured, compared with alendronate. ...
Source: Women's Health Weekly (2008-06-12)
|
